Randomized, placebo-controlled phase II study of efficacy of morphine for dyspnea in patients with interstitial lung disease: JORTC-PAL15

Matsuda Yoshinobu0 个研究点目标入组 50 人开始时间: 2019年6月27日最近更新: 2023年11月20日

适应症

试验速览

暂无简介。

•1.Patients who are diagnosed with ILD by two respiratory physicians and one respiratory radiologist
•2.Patients who have dyspnea at restdespite conventional treatment, with NRS 3 or more
•3.Patients who have normal liver and renal function ( AST 100 IU/L or less, ALT 100 IU/L or less, T-Bil 2.0 mg/dL or less, sCre 2.0 mg/dL or less), blood oxygen saturation levels (SpO2) 90% or more and partial pressure of carbon dioxide (PaCO2) 60 Torr or less (Supplemental oxygen was allowed)
•4.Adult patients (20 years old or older)
•5.Patients who has expected survival of 1 month or longer
•6.Patients who is capable of communication and did not have cognitive impairments
•7.Patients who provided written informed consents

•1.Patients who have contraindication for morphine
•2.Patients who use opioids
•3.Patients who have left heart failure (EF < 50%) confirmed by echocardiography
•4.Patients who have acute respiratory failure
•5.Patients who have infection that causes dyspnea
•6.Patients who have lung cancer that causes dyspnea
•7.Patients who have bronchial asthma attack
•8.Patients who have pneumothorax requiring thoracic drainage
•9.Patients who use mechanical ventilation
•10.Patients who have current or past history of drug abuse
•11.Patients who are pregnant

发起方

Matsuda Yoshinobu